The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identification of homologous recombination deficiency (HRD) by RAD51 in a tumor molecular profiling program for precision medicine.
 
Alba Llop-Guevara
Patents, Royalties, Other Intellectual Property - Patent WO2019122411A1: Methods based on the detection of RAD51 foci in tumor cells
 
Sara Arce-Gallego
No Relationships to Disclose
 
Mafalda Oliveira
Honoraria - Eisai Europe; Guardant Health; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; ITeos Therapeutics; Pierre Fabre; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Eisai; Novartis; Pierre Fabre; Roche
 
Sara Simonetti
No Relationships to Disclose
 
Cristina Viaplana
No Relationships to Disclose
 
Juan Francisco Grau
No Relationships to Disclose
 
Carmen García-Duran
No Relationships to Disclose
 
Isabel Pimentel
Honoraria - AstraZeneca/Merck; Novartis
Speakers' Bureau - Novartis
 
Paola Martínez
No Relationships to Disclose
 
Jose Jimenez
No Relationships to Disclose
 
Rodrigo Dienstmann
Employment - Oncoclínicas
Consulting or Advisory Role - Boehringer Ingelheim; Roche
Speakers' Bureau - Amgen; Ipsen; Libbs; MSD Oncology; Roche; Sanofi; SERVIER
Research Funding - Merck
 
Paolo Nuciforo
Honoraria - Bayer; MSD Oncology; Novartis
Consulting or Advisory Role - Bayer; MSD Oncology
Travel, Accommodations, Expenses - Novartis
 
Joan Carles
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZéneca; Bayer; Bristol-Myers Squibb; Johnson & Johnson/Janssen; MSD Oncology; Pfizer; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Johnson & Johnson
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); BN ImmunoTherapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera; Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen-Cilag International NV (Inst); Karyopharm Therapeutics (Inst); Laboratories Leurquin Mediolanum (Inst); Lilly (Inst); Medimmune (Inst); Millenium Pharamceuticals (Inst); Nanobiotix (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi Aventis GmbH (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; Ipsen; Roche
 
Ana Vivancos
Stock and Other Ownership Interests - Reveal Genomics
Consulting or Advisory Role - Bayer (Inst); Bristol-Myers Squibb (Inst); Guardant Health (Inst); Incyte (Inst); Merck (Inst); Roche (Inst)
Research Funding - Bristol Meyers Squibb (Inst); Incyte (Inst); Roche (Inst)
 
Ana Oaknin
Consulting or Advisory Role - AGENUS; Amgen; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Deciphera; Eisai; EMD Serono; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Medison; Merck Sharp & Dohme; Mersana; Novocure; PharmaMar; prIME Oncology; Roche; Roche; Shattuck Labs; Sutro Biopharma; Tesaro
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Agenus (Inst); Aprea Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Belgian Gynaecological Oncology Group (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Eisai (Inst); Immunogen (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Medimmune (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Mundipharma Research (Inst); Novartis Farmacéutica (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Sutro Biopharma (Inst); Tesaro (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche
 
Cristina Saura
Consulting or Advisory Role - AstraZeneca; Ax's Consulting; Byondis; Daiichi Sankyo; Eisai; Exact Sciences; Exeter Pharmaceuticals; ISSECAM; MediTech; Merck Sharp & Dohme; Novartis; Pfizer; Philips Healthcare; Pierre Fabre; Pint Pharma; Puma Biotechnology; Roche; Roche; Sanofi/Aventis; Seagen; Zymeworks
Research Funding - Aragon Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim España (Inst); Bristol-Myers Squibb (BMS) (Inst); Cytomx Therapeutics (Inst); Daiichi Sankyo (Inst); Genentech (Inst); German Breast Group (Inst); GlaxoSmithKline (Inst); InnoUp (Inst); International Breast Cancer Study Group (Inst); Lilly (Inst); Macrogenics (Inst); MedSIR (Inst); Menarini (Inst); Merus (Inst); Millennium (Inst); Millennium (Inst); Novartis Farmacéutica (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genomic Health; Novartis; Pfizer; Puma Biotechnology; Roche
 
Susana Aguilar
No Relationships to Disclose
 
Joaquin Mateo
Consulting or Advisory Role - Amgen; AstraZeneca; MSD; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Guardant Health; Janssen; Pfizer
Research Funding - AstraZeneca (Inst); Pfizer
Travel, Accommodations, Expenses - AstraZeneca
 
Judith Balmaña
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - AstraZeneca (Inst)
Patents, Royalties, Other Intellectual Property - Patent PCT/EP2018/086759 (WO2019122411A1)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Violeta Serra
Honoraria - AstraZeneca
Research Funding - AstraZeneca; Cyteir; Onxeo; Zenith Epigenetics
Patents, Royalties, Other Intellectual Property - Patent PCT/EP2018/086759 (WO2019122411A1)